Release date: 2024-07-09 15:52:53 Recommended: 220
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appointed by the World Health Organization (WHO) and director of the Microbiology Laboratory of the National Institute for Drug Control of Portugal, made an important technical support visit to the Lucius pharmaceutical factory in Laos.
This visit is an important opportunity for academic exchange and cooperation. The chairman of Lucius Pharmaceuticals personally met with Dr. Louis, and the two sides had in-depth communication on further academic exchanges and cooperation.
During his visit, Dr. Luis trained Lucius and those participating in the World Health Organization (WHO) laboratory pre-accreditation. He gave a detailed account of the requirements, experience and progress of the Portuguese National Institute for Drug Control, as well as the World Health Organization (WHO) for the prequalification of microbiological and sterile laboratories. He also shared the experience of the Portuguese National Institute for Drug Control in 2011 to achieve precertification.
This visit not only strengthened the academic exchanges and cooperation between the two countries in the field of microbiology, but also provided valuable technical support and guidance for the Lucius Pharmaceutical Factory in Laos. This is a landmark visit that is of great significance for the development of global public health.
In addition, the visit also marked the enhancement of Lucius Pharmaceuticals' position in the field of global public health. Not only have they received technical support from Dr. Luís Meirinhos Soares, Director of the Microbiology Laboratory at the National Institute for Drug Control in Portugal, but they have also been recognized by the World Health Organization (WHO).
This recognition is an affirmation of Lucius Pharmaceutical's expertise and rigorous attitude in the field of microbial testing and testing. They have always insisted on using state-of-the-art technology and equipment to ensure the quality and safety of their products. In addition, they actively participate in various academic exchanges and collaborations to improve their R&D capabilities and technical level.
This recognition is also a recognition of the hard work and professionalism of the employees of Lucius Pharma Laos who have always been people-oriented and focused on the professional development and welfare of their employees. They believe that only satisfied employees can provide quality products and services.
This recognition is a recognition of Lucius Pharma's contribution to the global public health field We look forward to their continued efforts in the future and their greater role in global public health.
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of L···【more】
Recommended:208Release date: 2024-07-09
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appoint···【more】
Recommended:221Release date: 2024-07-09
On October 19, 2023, the World Health Organization (WHO) conducted a comprehensi···【more】
Recommended:192Release date: 2024-07-09
At present, the competition in all walks of life is very fierce, especially in t···【more】
Recommended:158Release date: 2024-07-09
Here are some key points about Lucius Pharmaceutical:Lucius Pharmaceuticals has ···【more】
Recommended:291Release date: 2024-07-09
From the Black Sea, the most terrifying ocean on earth, to the Mediterranean Sea···【more】
Recommended:171Release date: 2024-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended:326Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended:197Release date: 2024-07-09
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) ···【more】
Recommended:154Release date: 2025-01-13
Recent advancements have reaffirmed the significance of liquid biopsy in the man···【more】
Recommended:151Release date: 2025-01-06
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Fo···【more】
Recommended:166Release date: 2024-12-30
The new indication involves the treatment of adult patients with locally advance···【more】
Recommended:157Release date: 2024-12-24
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont···【more】
Recommended:143Release date: 2024-12-17
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-C···【more】
Recommended:104Release date: 2024-12-13